Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Entertainment
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pliant Therapeutics, Inc.
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
May 24, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics to Participate in Upcoming Investor Events
May 10, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 09, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures
April 30, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
April 12, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
March 27, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
March 13, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
March 09, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
March 08, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics to Participate in Upcoming Investor Events
March 01, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics to Participate in Upcoming Investor Events
February 07, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
February 02, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 27, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
January 25, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
January 24, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Announces Proposed Public Offering of Common Stock
January 23, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
January 22, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
December 15, 2022
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics to Participate in Upcoming Investor Conferences
November 15, 2022
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 08, 2022
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
October 05, 2022
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PLRX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.